about
The activity of hsp90 alpha promoter is regulated by NF-kappa B transcription factorsAnnexin A1 induces skeletal muscle cell migration acting through formyl peptide receptorsRole of intracellular and extracellular annexin A1 in migration and invasion of human pancreatic carcinoma cellsNF-kappaB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors.Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes.Annexin A1 contributes to pancreatic cancer cell phenotype, behaviour and metastatic potential independently of Formyl Peptide Receptor pathway.Histone deacetylase inhibitors in the treatment of hematological malignancies.Cryptogenic stroke and diabetes: a probable link between silent atrial fibrillation episodes and cerebrovascular disease.Benzodiazepine Scaffold as Drug-like Molecular Simplification of FR235222: A Chemical Tool for Exploring HDAC Inhibition.Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid.Role of Annexin A1 in mouse myoblast cell differentiation.Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-kappaB signalling pathway in thyroid cancer cells.Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of annexin A1.Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl-piperazine.Dexamethasone inhibits TRAIL-induced apoptosis of thyroid cancer cells via Bcl-xL induction.Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.Hypoxia regulates ANXA1 expression to support prostate cancer cell invasion and aggressiveness.NF-kappaB protects Behçet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins.Activation of NF-kappaB/Rel transcription factors in human primary peripheral blood mononuclear cells by interleukin 7.Effects of Prisma® Skin dermal regeneration device containing glycosaminoglycans on human keratinocytes and fibroblasts.Evaluation of in situ injectable hydrogels as controlled release device for ANXA1 derived peptide in wound healing.miR-196a Is Able to Restore the Aggressive Phenotype of Annexin A1 Knock-Out in Pancreatic Cancer Cells by CRISPR/Cas9 Genome EditingAnnexin A1 May Induce Pancreatic Cancer Progression as a Key Player of Extracellular Vesicles Effects as Evidenced in the In Vitro MIA PaCa-2 Model SystemTight Glycemic Control May Increase Regenerative Potential of Myocardium during Acute InfarctionDefect of Interleukin-2 Production and T Cell Proliferation in Atopic Patients: Restoring Ability of the CD28-Mediated Activation PathwayAnalysis of peripheral blood normal and malignant cells with the novel murine monoclonal antibody UN2Differential expression of surface membrane growth hormone receptor on human peripheral blood lymphocytes detected by dual fluorochrome flow cytometryBAG3 protein regulates cell survival in childhood acute lymphoblastic leukemia cellsModulation of cell apoptosis by AIRInduction of annexin-1 during TRAIL-induced apoptosis in thyroid carcinoma cellsTFF1 Promotes EMT-Like Changes through an Auto-Induction MechanismPCL/Mesoglycan Devices Obtained by Supercritical Foaming and ImpregnationMesoglycan induces keratinocyte activation by triggering syndecan-4 pathway and the formation of the annexin A1/S100A11 complex
P50
Q28242458-2F654372-94F1-43A5-812F-A6A7A1EBE980Q28512121-1B2297AA-7912-4597-9544-1674389E7163Q35522087-60A7BB23-9C73-4823-B9AE-4FC5E870A2D9Q35566335-403C3376-FA53-4F21-9C67-BC0C772FFDAEQ36415163-D669F736-6473-45CF-9C80-B9EF7441EDF5Q37093146-9E06D38B-E54F-4A65-8B8B-ED26A39F3D80Q37874311-707B65A5-2E96-4E11-AFC4-D3DA27A3F262Q38181527-84D013DB-6203-4C66-855B-61BFF71D70F7Q38750269-CAC55013-6D16-4E11-BEB9-57DBF2B016F7Q38840434-97D8FFC9-2296-4B70-8273-C873F030FDD1Q39688368-6A4C1BE2-B572-4D04-A08D-3BD397CCE5A3Q39831740-8EDC9465-5D3E-466A-9F62-E0670043D564Q40009668-B7549F05-C7A2-4831-A72E-2FABD0B9088EQ40179001-37AACA83-097C-4F2F-B186-658BB9E6B08CQ42503373-6C0C868E-FC24-4F16-AB75-C49E8264A0C4Q42745610-D5F1D5D2-4749-4FFA-87F6-C5828EBB1A6FQ43283331-86B71FD8-6A36-476D-A1DC-F363EA8157C4Q46573592-EEA36169-9B47-4F8F-A0AE-7ED20CC8AA4CQ47347734-C0B9C942-3937-4A6A-88D4-1697DFE560D4Q47810610-2121B077-7003-4655-9073-2C7C5102DC81Q53381140-B9242CE2-9679-4FD0-85A0-02520099CADCQ57595606-86F31F04-0D03-4642-B86D-8066CA2FF876Q60919625-7E859949-6712-413B-8814-0500B0C85EFBQ61155585-D9268D54-E73A-4AAC-B232-B9EB62FB9D3CQ61863601-0E255A6E-663B-498F-8630-298AD20C4F8AQ72427663-C1E95389-7C90-4D09-94D4-3BC2B6009733Q72810081-0EF3CA61-DA9E-4B7D-8E64-546B4E7A5A26Q79290662-2F530EFC-7805-4589-A8FA-567BD26833BEQ80633290-0D1FF6EC-836F-4208-832D-793558D9227FQ81677010-5E0EA819-B8CB-479E-A2EF-104C58318A87Q89575253-C773A86C-8FCC-4479-8E6F-79B519D93618Q91513516-D39C3E4C-42C9-4719-BC6B-F1DF4762650AQ92961203-B9BED85A-B9CB-48A2-9B74-2D2560E05E47
P50
description
researcher ORCID ID = 0000-0002-6945-5295
@en
wetenschapper
@nl
name
Antonello Petrella
@ast
Antonello Petrella
@en
Antonello Petrella
@es
Antonello Petrella
@nl
type
label
Antonello Petrella
@ast
Antonello Petrella
@en
Antonello Petrella
@es
Antonello Petrella
@nl
prefLabel
Antonello Petrella
@ast
Antonello Petrella
@en
Antonello Petrella
@es
Antonello Petrella
@nl
P106
P1153
7003298013
P31
P496
0000-0002-6945-5295